Agendia Demonstrates Accessibility and Affordability of MammaPrint and BluePrint in Europe at ESMO Breast Cancer 2022
Next-generation sequencing version of MammaPrint and BluePrint enables decentralized testing Read More
Next-generation sequencing version of MammaPrint and BluePrint enables decentralized testing Read More
Company showcases pipeline developments and sub-studies from the revolutionary FLEX Read More
January 27, 2022 By Leo O’Connor NEW YORK ─ As part Read More
New analysis in peer-reviewed journal Genes, Chromosomes and Cancer Read More
AI solution will expand Agendia’s testing platform in the Brazilian Read More
Multi-year partnership to advance the use of next-generation sequencing for Read More
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – January 6, 2022 Read More
Additional research from the real-world FLEX Registry focuses on age Read More
Data signal importance of serial genomic testing in order to Read More
ER+ tumors reclassified by BluePrint as Basal-type occur at a Read More